Introduction {#S1}
============

Celiac disease (CD) is a chronic, immune-mediated enteropathy triggered by the ingestion of gluten containing grains in genetically susceptible individuals, expressing the HLA-class 2 molecules DQ2 or DQ8 ([@B1]). Clinical features vary greatly from asymptomatic to classical or atypical presentation. Gluten-induced small-bowel (SB) mucosal histological damage develops gradually, from lymphocytic infiltration of the epithelium to crypt hyperplasia and further to villous atrophy ([@B2]). Histological confirmation of CD can be challenging, as related to the quality of the biopsy specimens ([@B3]) as well as the patchiness of the intestinal lesions ([@B4]). Furthermore, similar SB mucosal abnormalities can be found in other conditions such as giardiasis, viral infections, food allergy, and autoimmune enteropathy.

Potential celiac disease (PCD) is a well-known condition, characterized by a positive serology for CD with an architecturally normal intestinal mucosa. Timing of progression toward classical CD has not clearly been established in PCD, although a recent study indicates that 30% of children with PCD left on a normal diet develop villous atrophy within 4 years ([@B5]). In another study performed in an at-risk population (first-degree relatives), 5% of children with PCD developed overt CD within 2 years ([@B6]). In this context, the search for a specific marker with a high prognostic value is extremely appealing.

It was initially observed that the SB epithelial basement membrane of CD patients contains specific deposits of immunoglobulin A (IgA) ([@B7]), which were subsequently shown to be targeted against extracellular transglutaminase 2 (TG2) ([@B8]). The original technique to detect the presence of anti-TG2 IgA extracellular deposits was introduced by Karponay-Szabò et al. ([@B8]). In the original paper, authors accurately described a method of detecting the co-localization of IgA deposits to TG2 by immunofluorescence (Figures [1](#F1){ref-type="fig"}A,B). Based on this technique, they demonstrated presence of TG2 deposits in the intestinal mucosa of CD patients, PCD patients, and subjects with dermatitis herpetiformis (DH).

![**Small-bowel mucosal immunofluorescence staining of IgA (green) and transglutaminase-2 (red) and co-localization of IgA and TG2 in yellow (arrow)**. In **(A)** a healthy control (no co-localization), in **(B)** a celiac patient with evidence of co-localization (arrow).](fmed-01-00009-g001){#F1}

So far several studies investigated the presence and the diagnostic role of TG2 IgA deposits in adults and children with either overt CD or PCD. Intestinal deposits have been found to be a constant feature in overt CD at diagnosis, while their intensity seems to decrease on a gluten-free diet (GFD). Their role in PCD is less clear, with some studies reporting a positive value in predicting an intestinal damage. Furthermore intestinal deposits have been described in other gluten-related disorders (DH and GA) and in other autoimmune conditions, such as type-1 diabetes (T1D).

The determination of intestinal IgA deposits requires a fresh biopsy sample to be stored in liquid nitrogen. It is a time consuming and expensive analysis, requiring an expert pathologist in a specialized center. In consideration of such limitation and the growing amount of data now available, the exact diagnostic role of TG2 IgA deposits needs to be clarified. In this article, we provide a systematic review of the existing literature on the diagnostic value of intestinal deposits in CD and other gluten-related disorders, aiming to answer the question whether this test can be used as an early marker of disease progression in PCD.

Materials and Methods {#S2}
=====================

Before starting the search and review process, we defined the review protocol, specifying the research question, inclusion and exclusion criteria, search strategies, quality criteria, methods for extracting related data, and statistical methods.

All studies (including cross-sectional, cohort, case--control, and case-series) were considered eligible. Case reports, abstracts presented at meetings, and articles not published in English language were excluded. Our search was focused on studies recruiting patients of all ages with overt CD (associated with some degree of villous atrophy at the SB biopsy), PCD, other gluten-related diseases (gluten-sensitivity, GA, and DH), or other autoimmune conditions \[T1D, inflammatory bowel disease (IBD), autoimmune thyroiditis\], where the prevalence of intestinal anti-TG2 deposits has been investigated, as a primary or secondary outcome. Overt CD was defined according to the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) criteria ([@B9]). PCD was defined as the positivity of serological markers \[anti-transglutaminase (TTG) and/or anti-endomysium (EMA) antibodies\] in presence of normal SB histology or minimal histological changes (Marsh 0--1). Studies giving ambiguous definitions of PCD or considering PCD patients together with gluten-sensitive or latent CD patients were not considered. No publication date or publication status was imposed.

Relevant studies were identified through electronic databases and scanning reference lists of eligible studies. Our search was applied to the Medline database using PubMed by combining key words for gluten-related disorders (CD, PCD, gluten intolerance, gluten-sensitivity, GA, DH, autism, type-1 diabetes) and search terms for intestinal deposits (intestinal deposits, IgA intestinal deposits, anti-TG2 intestinal deposits, intestinal anti-tissue transglutaminase, immunofluorescence). All studies were published between 1950 (start of Medline) and December 2013. To ascertain the validity of the eligible studies, the study design, the size, and representativeness of the study population (i.e., the presence of selection bias), the validity of outcomes (risk of confounding or bias), and the quality of the statistical analysis were taken into account.

The following informations were extracted from each study: (1) characteristics of participants (number, age, diagnosis and method of diagnosis, diet, length of diet); (2) serological markers \[TTG, EMA, anti-gliadin antibodies (AGA) IgA and IgG\]; (3) prevalence, type, and features of intestinal deposits (anti-TG2, anti-endomysium and AGA, intensity, submucosal or perivascular, homogeneous or heterogeneous pattern).

Results {#S3}
=======

Study characteristics {#S3-1}
---------------------

Overall we identified 25 eligible studies. Two of them were subsequently excluded because prevalence of TG2 deposits was not reported in the results in one and intestinal IgA deposits instead of TG2 deposits were considered in the other ([@B10], [@B11]). We found 18 studies performed in celiac (overt and potential) patients, 9 of them in pediatric groups. The remaining five studies were focused on children with T1D and cerebral palsy and adult with GA, DH, and gluten-sensitivity. Table [1](#T1){ref-type="table"} summarizes the features of the 23 selected studies.

###### 

**Summary of included studies evaluating presence and significance of intestinal deposits in celiac disease and other groups of patients**.

  No.   Source (first author)     Study design   Number of participants   Group 1 (*n*)   Inclusion criteria                                     Group 2 (*n*)   Inclusion criteria             Controls (*n*)   Age                  Outcomes
  ----- ------------------------- -------------- ------------------------ --------------- ------------------------------------------------------ --------------- ------------------------------ ---------------- -------------------- ---------------------------------------------------------------------------------------------------------------------
  1     Tosco ([@B5])             O, Cohort, P   106                      106             PCD                                                    --              --                             --               6 years, 8 months    Histological and serological follow-up study in children with PCD
  2     Korponay-Szabo ([@B8])    O, Cohort      33                       10              Developing CD                                          11              CD                             12               8 years, 1 month     Prevalence of intestinal and extra intestinal TG2 IgA deposits in early stage CD and CD
  3     Salmi ([@B12])            O, C.S.        427                      223             Untreated CD                                           66              PCD                            138              45 years             Comparison between conventional and new histological parameters (including TG2 deposits) in diagnosis of CD and PCD
  4     Salmi ([@B13])            O, Cohort, P   75                       25              EMA− Marsh 1                                           25              PCD                            25               39 years             Role of TG2 IgA deposits in detection of early developing CD
  5     Koskinen ([@B14])         O, C.S.        254                      71              CD on short term GFD                                   105             CD on long term GFD            78               47 years             Prevalence of TG2 IgA deposits in CD at diagnosis and after GFD
  6     Koskinen ([@B15])         O, C.S.        103                      48              LCD, PCD                                               13              CD                             42               37 years             Diagnostic value and gluten-dependency of TG2 IgA deposits in overt and mild enteropathy CD
  7     Kaukinen ([@B16])         C, E           93                       41              Suspected CD (normal villi, ↑γδ+ IELs)                 18              CD                             34               46 years, 9 months   Prevalence of TG2 IgA deposits in early stage CD before and after dietary intervention
  8     Maglio ([@B17])           O, C.S., R     344                      144             Untreated CD                                           109             PCD                            91               6 years, 3 months    Prevalence of TG2 IgA deposits in CD and PCD
  9     Maglio ([@B18])           O, C.S.        203                      104             CD \<2 years                                           179             CD \> 2 years                  18               15 months            Prevalence of TG2 IgA deposits in CD children \<2 years, negative for serum anti-TG2 Ab
  10    Tosco ([@B19])            O, C.S.        40                       12              CD                                                     28              PCD                            39               7 years              Comparison of Ab secretion to culture supernatants and TG2 deposits in CD and PCD
  11    Kurppa ([@B20])           O, Cohort, P   76                       42              Untreated CD                                           17              PCD                            17               11 years             Evaluation of deposits at diagnosis in CD, PCD, and controls
  12    Salmi ([@B21])            O, C.S., P     193                      22              CD, EMA+                                               151             CD, EMA−                       20               47 years             Comparison of clinical and histological features (including TG2 deposits) in EMA negative and positive CD
  13    Koskinen ([@B22])         O, C.S.        65                       28              Responsive CD                                          27              Non-responsive CD              10               48 years             Role of TG2 deposits in distinguishing non-responsive CD from other enteropathies
  14    Koskinen ([@B23])         C, E.          23                       13              CD on GFD + oats challenge                             10              CD on GFD + gluten-challenge   --               13 years             Response of TG2 deposits to oats challenge
  15    Salmi ([@B24])            O, C.S.        74                       47              Untreated DH                                           27              DH on GFD                      --               47 years             Prevalence of TG2 IgA deposits in DH and relation to GFD
  16    Hadjivassiliou ([@B25])   O, C.S.        36                       97              GA, other ataxia                                       10              CD                             10               59 years, 6 months   Deposition of brain and intestinal TG2 IgA deposits in patients with GA
  17    Stenberg ([@B26])         O, C.S.        16                       16              CP with CD                                             --              --                             --               11 years             Detection of early signs of CD in CP
  18    Maglio ([@B27])           O, C.S.        100                      33              T1D on GCD                                             12              Untreated CD                   55               11 years             Prevalence of TG2 IgA deposits in children with T1D
  19    Borrelli ([@B28])         O, C.S.        25                       16              IgA--D, Marsh 0--1; nine non-CD; seven PCD (IgG pos)   9               IgA--D; CD (Marsh 2--3)        16               7 years, 1 month     Detection of TCR γδ IELs and TG2 IgM deposits in IgA--D subjects
  20    Ruuskanen ([@B29])        O, Cohort, P   2815                     49              AGA+, tTG−, HLA+, no CD                                --              --                             52               69 years             Detection of minor inflammatory changes in AGA persistently positive non-CD patients
  21    Tosco ([@B30])            O, C.S.        91                       39              PCD                                                    18              Serum Ab negative, IEL+        34               7 years, 1 month     Prevalence of TG2 IgA deposits in PCD
  22    Stenman ([@B31])          O, C.S.        31                       5               Untreated CD                                           20              CD on GFD                      6                54 years             Correlation between Ab secretion to culture supernatants and TG2 deposits
  23    Tack ([@B32])             C, E           16                       7               CD gluten-challenge + placebo                          7               CD gluten-challenge + EN PEP   --               55 years             Evaluation of safety and immunogenic effects of AN-PEP in CD

*C, comparative; O, observational; E, experimental; P, prospective; R, retrospective; CD, celiac diseases; PCD, potential celiac disease; LCD, latent celiac disease; GFD, gluten-free diet; T1D, type-1 diabetes; CP, cerebral palsy; GA, gluten-ataxia; AN-PEP, *Aspergillus niger* prolylendoprotease; IgA D, IgA deficiency; DH, dermatitis herpetiformis; EMA, anti-endomysium antibodies; tTG, anti-transglutaminase antibodies*.

Intestinal deposits in CD at diagnosis {#S3-2}
--------------------------------------

Ten studies investigating the presence of intestinal TG2 deposits in patients with overt CD at diagnosis were identified and five were performed in children (median age 6.5 years). The included studies involved a total of 863 CD patients, presence of deposits was investigated only in 81.7% of cases. Results of the included studies are summarized in Table [2](#T2){ref-type="table"}.

###### 

**Summary of the included studies evaluating the presence of intestinal TG2 deposits in overt celiac disease (CD)**.

  Reference (first author)   Age (years), median (range)   Overt CD (*n*)   TG2 IgA deposits: prevalence   Diagnostic value (%)
  -------------------------- ----------------------------- ---------------- ------------------------------ ----------------------
  Korponay- Szabo ([@B8])    78 (4.4--32)                  10               10/10                          SE: 100
                                                                                                           SP: 100
  Salmi ([@B12])             42 (16--81)                   223              35/35                          SE: 100
                                                                                                           SP: 100
  Koskinen ([@B14])          47 (4--79)                    261              261/261                        SE: 100
                                                                                                           SP: 82
  Koskinen ([@B15])          47 (28--68)                   13               13/13                          SE: 100
                                                                                                           SP: 95.9
  Kaukinen ([@B16])          47 (22--68)                   18               6/6                            SE: 100
                                                                                                           SP: 100
  Maglio ([@B17])            63 (6 months--16 years)       144              138/144                        SE: 95.8
                                                                                                           SP: 87.9
  Tosco ([@B19])             7                             12               12/12                          SE: 100
                                                                                                           SP: 80
  Maglio ([@B18])            \<2, 15 months                \<2 years: 56    \<2 years: 41/56               SE: 73.2
                             \>2, 7 years                  \>2 years: 40    \>2 years: 40/40               SE: 100
                                                                                                           SP: ne
  Kurppa ([@B20])            10 (1--15)                    42               42/42                          SE: 100
                                                                                                           SP: ne
  Salmi ([@B21])             55 (20--79)                   22 EMA−          18/18                          SE: 100
                             40 (16--81)                   22 EMA+          17/17                          SP: 100

*SE, sensitivity; SP, specificity; ne, not evaluable (no control group)*.

Adults with untreated CD had TG2-targeted autoantibodies deposition in the SB mucosa in 100% of cases ([@B12]--[@B16]), while there was more variability in the pediatric population. By studying 144 untreated CD children, Maglio and co-workers found that TG2 IgA deposits had a sensitivity of 95.8% in diagnosis of CD ([@B17]). The same authors reported a different prevalence of TG2 IgA deposits in younger children (\<2 years of age) compared to older groups. They found mucosal deposits in 73.2% of infants, while the detection rate of serum EMA and/or anti-TG2 IgA was 82% in the same population. Conversely all children older than 2 years of age were positive for anti-TG2 IgA intestinal deposits and had serum EMA and circulating TTG antibodies ([@B18]). Three pediatric studies showed that deposits had a sensitivity of 100% in untreated CD, confirming adult results ([@B8], [@B19], [@B20]). Furthermore intestinal TG2-targeted autoantibody deposits had the best sensitivity values in detecting untreated CD with villous atrophy comparing with other CD markers \[increased density of villous tip intraepithelial lymphocytes (IELs), increased density of γδ+ IELs, increased density of CD3+ IELs, serum IGA-class autoantibodies\] in adult setting ([@B12]).

Overall, the mean value of specificity in all selected studies (either adult patients or children) was 94.15% (range 82--100%). Two studies found the intensity of these deposits significantly higher in the celiac patients than in patients with PCD ([@B17], [@B20]). Interestingly Salmi et al. found that in CD patients without serum EMA, TG2 IgA were still deposited and detectable in the SB mucosa in all cases ([@B21]). However, the same authors found that the intensity of deposits did not correlate with the severity of the mucosal lesion ([@B21]).

Intestinal deposits in PCD {#S3-3}
--------------------------

Several studies investigated the presence and features of intestinal deposits in subjects with PCD, both in children and adults. Six studies included a well-defined group of PCD patients, their main characteristics, and results are summarized in Table [3](#T3){ref-type="table"}.

###### 

**Summary of the included studies evaluating TG2 deposits in potential celiac disease (PCD)**.

  Reference (first author)   Age, median (range)                                PCD (*n*)   PCD: definition                 TG2 IgA deposits: prevalence   Diagnostic value (%)   Intensity                                              Results of follow-up studies and comparison with other markers
  -------------------------- -------------------------------------------------- ----------- ------------------------------- ------------------------------ ---------------------- ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------
  Tosco ([@B5])              6 years, 8 months (18 months--16 years)            106         TTG or EMA+, Marsh 0--1         66/102                         SE: 64.7 SP: ne        --                                                     At 4 years follow-up, 30.8% develop overt CD. TG2 deposits in the first biopsy was the only marker to predict evolution toward villous atrophy
  Salmi ([@B13])             40 years (16--81)                                  25          EMA+, Marsh 0--1                12/12                          SE: 93                 --                                                     TG2 had the best SE and SP for detecting early developing CD
                                                                                                                                                           SP: 93                                                                        
  Maglio ([@B17])            6 years, 4 months (6 months--16 years)             109         TTG+, Marsh 0--1                74/109                         SE: 67.9 SP: 87.9      Intensity significantly weaker in PCD compared to CD   --
  Tosco ([@B19])             7 years (2--17)                                    28          TTG+, Marsh 0--1                19/28                          SE: 68                 --                                                     --
                                                                                                                                                           SP: 80                                                                        
  Kurppa ([@B20])            11 years (4--17)                                   17          EMA+, Marsh 0--2                17/17                          SE: 100                Less intense in PCD than CD                            Seven of eight on a GCD develop overt CD within 2 years
                                                                                                                                                           SP: 100                                                                       
  Tosco ([@B30])             7 years, 1 month (9 months--17 years, 11 months)   39          EMA or TTG+, normal histology   33/39                          SE: 85 SP: 91          --                                                     --

*SE, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predictive value; EMA, anti-endomysium antibodies; TTG, anti-transglutaminase antibodies; PCD, potential CD; ne, not evaluable (no control group)*.

In a total of 301 patients with PCD (289 children and 12 adults), the prevalence of intestinal deposits ranged from 68 to 100%. The intensity of deposits was described in four studies, all of them showing that TG2 deposits were significantly less intense if compared to subjects with overt CD ([@B17], [@B20], [@B22], [@B23]). Furthermore, four studies detected a patchy distribution of intestinal deposits, characterized by areas with strong staining, with weaker staining areas and areas completely negative ([@B5], [@B17], [@B19], [@B22]) Only one prospective study, aiming to investigate the natural history of PCD, followed-up children with PCD with repeated biopsy ([@B5]). Evaluation of intestinal deposits was not the primary outcome of the study and power calculation to address the research question was not mentioned in the article. Comparing data from 12 patients that developed villous atrophy and 27 who did not, authors found that only the presence of intestinal deposits in the first biopsy was different in the two groups, speculating that the presence of TG2 deposits could predict the evolution toward villous atrophy.

Intestinal deposits in CD during follow-up: Prevalence, correlation with other CD markers, and response to gluten-challenge {#S3-4}
---------------------------------------------------------------------------------------------------------------------------

Five studies specifically addressed the question whether and when TG2 deposits disappear after establishing a GFD. Koskinen et al. compared TG2 IgA deposits after short term (1 year) and long term (2--41 years) GFD in a large cohort of pediatric and adult CD patients. They found that deposits were still positive in 82 and 56%, respectively ([@B14]). These results were confirmed in another study in adults, where 28 patients still showed presence of deposits in 75% of cases after 1 year of GFD ([@B24]). Interestingly, CD markers were found to disappear in a sequential order during a GFD. TG2 deposits disappeared after normalization of serum autoantibodies, SB villous atrophy, and the densities of CD3+ IELs. The increased density of γδ+ IELs was the only marker that disappeared later than the deposits ([@B14]). The same authors analyzed 27 adults with non-responsive CD and found that 6 patients with poor adherence to the GFD had CD autoantibodies in both serum and SB mucosa. In the remaining 21 non-responsive CD patients with good adherence to the GFD, only 4 had serum autoantibodies while 20 (95%) had deposits in the SB mucosa ([@B24]). In addition, the intensity of deposits has been shown to gradually decrease during the GFD ([@B14], [@B15]).

Intestinal deposits were also investigated as an early marker of intestinal damage after gluten-exposure. In an interventional study, Koskinen et al. analyzed 23 CD children in clinical, serological, and histological remission, 13 were randomized to undergo an open oats challenge and 10 a gluten-challenge (GC) for 2 years. At baseline, weak-to-moderate TG2 IgA deposits were present in 4 of 13 in the oat challenge group and in 3 of 10 in the GC group. In the oats group, there was no significant change in the intensity of the deposits within 2 years, while in the gluten group the intensity of the deposits clearly increased and decreased again on a GFD. The intensity of deposits correlated well with serum TG2-antibody levels and the severity of SB mucosal villous damage ([@B23]).

In another study by Kaukinen et al., 41 adults with suspected CD (increased density of mucosal γδ+ IELs but normal villous morphology) were randomized to GFD or GC for a 6 months period. Using a clinical score, 11 out of 41 patients were defined as having a gluten-related disorder (5 in the GC and 6 in GFD group). In this subgroup, TG2 deposits were positive in 10 out of 11 and intensity increased upon GC and again decreased on GFD. Conversely IgA deposits were present in only 3 out of 30 patients with suspected CD with no clinical signs of gluten-sensitivity ([@B16]).

Intestinal deposits in other gluten-related disorders, autoimmune conditions, and IgA deficiency {#S3-5}
------------------------------------------------------------------------------------------------

A few studies investigated the prevalence and significance of intestinal deposits in other gluten-related disorders. In subjects with DH, the presence of cutaneous IgA deposits directed against TG3, as a marker of the disease, is well-established. The first study by Karponay-Szabò et al. investigating the presence of intestinal deposits in CD also enrolled 11 patients with DH ([@B8]). TG2 deposits were present in seven of them (63%) who had a normal villous architecture and two of them were negative for circulating EMA. One single study specifically explored the intestinal TG2 deposits in DH detecting them in 79% of untreated DH patients (with moderate or severe intensity) and in 41% of GFD treated DH patients (all with weak intensity). The presence and the intensity of the deposits were strongly correlated with the degree of the intestinal damage ([@B25]).

A small study ([@B26]) reported the presence of anti-TG2 intestinal deposits in 100% of nine patients with GA, and the lack of TG2 deposits in a group of patients with other causes of ataxia and positivity for serum AGA. Stenberg et al. failed to demonstrate an increased prevalence of intestinal TG2 deposits in children with cerebral palsy and elevated levels of CD-related sero-markers (AGA or TTG). In this group of 16 patients, only 1 showed IgA co-localizing with TG2 in the SB mucosa, suggesting CD at an early stage ([@B27]).

Interestingly, a high percentage of children with T1D on a normal diet presented with mucosal deposits, irrespective of the presence of circulating TTG antibodies. TG2 intestinal deposits were found in 78 and 58% of T1D children with circulating anti-TTG or not, respectively. Authors further examined molecular features of TG2 deposits, showing that only in the T1D group with positivity of serum TTG, the TG2 deposits had the same molecular characteristics found in CD-TG2 deposits. Particularly the serum-positive T1D patients showed a preferential involvement of the heavy-chain variable region-5 (VH5) antibody gene family, as well as in CD patients ([@B28]). In another study by Tosco et al., 20 T1D patients were enrolled as a control group and TG2 deposits were detected in 5 of them (25%) ([@B19]).

The presence of intestinal deposits was also investigated in CD children with IgA deficiency. For this purpose, immunofluorescence analysis of IgM anti-TG2 deposits in the SB biopsy of 25 CD children with IgA deficiency, 12 untreated CD with normal IgA levels, 9 PCD with IgA deficiency, and 16 healthy controls was described by Borrelli et al. Intestinal IgM deposits were more prevalent in subjects with CD compared to PCD, but did not discriminate accurately CD from PCD in this group with IgA deficiency ([@B29]).

Intestinal deposits in control groups {#S3-6}
-------------------------------------

Overall, 17 studies included a control group, all of them included patients with negative CD sero-markers, that underwent SB biopsy for GI disorders or other symptoms. The final diagnosis of these patients were functional dyspepsia, irritable bowel syndrome, gastro-esophageal reflux disease, multiple food intolerance, cow's milk allergy, IBD, iron deficiency anemia, failure to thrive, recurrent abdominal pain, dyspepsia, and T1D. Ten studies did not find intestinal TG2 IgA deposits in the control group ([@B8], [@B12], [@B16], [@B18], [@B20], [@B21], [@B24], [@B26], [@B29], [@B30]). Conversely, six studies detected TG2 IgA deposits in a minority of control subjects with a prevalence ranging from 5 to 20%. Tosco et al. found that 3/34 (8.8%) children with normal villous morphology presented TG2 IgA deposits ([@B22]). Maglio et al. identified TG2 IgA deposits with a patchy distribution and weak intensity in 11/91 (12%) children, among these 77% had normal mucosa (Marsh 0, 1) whilst 23% had SB mucosa classified as Marsh 3a, but no serological evidence of CD ([@B17]). Tosco et al. enrolled 39 control children, of whom 20 had T1D. Deposits were positive in 6/30 (20%) with a patchy distribution and among these 5/6 had T1D ([@B19]). Maglio et al. reported on 28 control patients without CD. Among these, 4/28 (14.2%) had TG2 IgA deposits, of whom 3 were affected with IBD ([@B28]). Koskinen et al. described the presence of deposits in adult controls in 14/78 (18%) with a weak, often patchy distribution ([@B14]). In another study, the same authors enrolled 42 control patients with suspicion of CD but no evidence of villous atrophy in two consecutive biopsy samples. HLA DQ2 or DQ8 were present in 19/42 and 4 patients presented CD serum antibodies at the onset, therefore they have to be considered potential. TG2 IgA deposits were present initially in 1/22 (5%) and in 3/39 (8%) patients on a gluten containing diet in the follow-up biopsy ([@B15]). In an *in vitro* study by Stenman et al. ([@B31]), authors did not find EMA antibodies in organ culture supernatants derived from non-CD biopsies, but they did not specifically search intestinal deposits in the control group.

Comparison between intestinal deposits and antibodies secreted into the culture supernatant {#S3-7}
-------------------------------------------------------------------------------------------

Two studies compared the secretion and the deposition of TG2 antibodies at the intestinal level ([@B19], [@B31]). Tosco et al. compared the detection of mucosal deposits to the measurement of antibodies secreted into culture supernatant. In overt CD patients, either TG2 deposits or antibodies secretion in the supernatant (higher than the cut-off value) were detectable in 100% of patients, with no differences when samples were cultured with medium alone or after 24 h of P31--43 or peptic tryptic gliadin digest (PTG). In PCD, the presence of deposits was 67% at baseline and 60 and 90% after 24 h incubation with medium alone and P31--43 or PTG, respectively. Conversely, 96.4% of PCD had IgA antibodies in the supernatant higher than the cut-off (with medium alone) and 92% after 24 h P31--43 or PTG *in vitro* stimulation. In controls, the baseline prevalence of deposits (20%) decrease after culture with medium (7%) and increase after *in vitro* gluten stimulation (36%). In the same group of controls, production of antibodies in the supernatant was 7 and 5% after culture with medium and 24 h P31--43 or PTG incubation. Therefore, authors found the measurement of anti-TG2 in culture supernatants to be more sensitive and specific than the detection of mucosal deposits to reveal mucosal production of anti-TG2 antibodies in CD, showing a sensitivity of 97.5 versus 77.5% and a specificity of 92.3 versus 80% of anti-TG2 in supernatant and mucosal deposits detection, respectively ([@B19]).

Stenman et al. demonstrated that only biopsies derived from patients on a short-term GFD and still having positive intestinal TG2 IgA deposits were able to secrete EMA into the culture supernatant, and speculated that autoantibody secretion in organ culture supernatant of biopsies from treated CD patients reflected the presence of positive intestinal TG2 IgA deposits ([@B31]).

Discussion {#S4}
==========

An extensive review of the literature indicates that intestinal deposits of anti-TG2 IgA are detectable in almost all patients with CD at diagnosis, the only exception being represented by children younger than 2 years of age, where the sensibility of the test is 73%. This data may simply reflect the natural fluctuation of these autoantibodies in serum as previously observed ([@B6]). The specificity of this tool varies from 80 to 100% at diagnosis. Control groups were found to show deposits in 5--20% of cases, with the highest prevalence being described in T1D and IBD patients. Both these conditions are well-known autoimmune disorders, characterized by an important role of an environmental component and frequent finding of CD serological markers. Therefore, the presence of intestinal deposits is not entirely surprising in these conditions, and suggests a possible role of gluten as a disease trigger.

No studies specifically investigated the correlation between the presence of intestinal deposits and the clinical presentation of CD. This would be particularly important in the context of the new ESPGHAN diagnostic criteria for CD. According to the new European criteria ([@B33]), diagnosis of CD in patients with a classical clinical picture, high antibody titer, and HLA predisposition does not require a SB biopsy. Conversely, children with no clinical symptoms and/or low titer antibodies still need the SB biopsy. In this subgroup of patients, the validation of a further histological marker, i.e., the intestinal TG2 deposits, could be useful.

Results from follow-up studies show that the intestinal deposits slowly disappear after starting treatment with the GFD. In comparison with the serological markers, intestinal deposits tend to disappear later, being still detectable in 56% of patients after many years of GFD (2--42 years). In the same individuals, serological markers were positive only in 15% of patients. Factors influencing the persistence of IgA deposits have not been specifically investigated, particularly we did not find studies correlating the presence of deposits with the adherence to the diet. However, it is interesting to note that the deposits were frequently detectable in a large proportion of patients with non-responsive CD reporting good adherence to the GFD, indicating that in this context their presence may reflect the celiac inflammatory process and not simply the gluten consumption.

Overall few data are available on the possible role of TG2 deposits as an early marker of gluten-exposure during a GC, therefore no conclusion can be drawn on this issue. To test their performance in detecting gluten effects at the intestinal level in CD patients, results from interventional and specifically designed studies (both *in vitro* and *in vivo*) are warranted.

As a marker of early damage in PCD, TG2 deposits were found in a high percentage of patients of all ages at first biopsy, ranging from 68 to 100% of cases. Unfortunately, there are no prospective studies specifically designed to test the sensitivity of intestinal deposits in predicting the development of villous atrophy. Data from a pediatric case-series (39 re-biopsied PCD children) seem to indicate that the finding of TG2 deposits at first observation is a risk factor for developing CD, but these data have never been replicated in larger studies and with a longer period of follow-up. Their application as a predictive tool in PCD continues to be an appealing but still not clearly defined option. In comparison with other methods of intestinal antibodies detection, TG2 deposits were found to be less sensitive and specific than the measurement of anti-TG2 in culture supernatants in PCD at diagnosis ([@B19]). Measurement of intestinal antibodies in the culture supernatant is an easier technique, compared to TG2 deposits, and, being an ELISA test, is less influenced by the operator's ability. Therefore the pros and cons of these two promising tools need to be compared in prospective studies, aiming to characterize the precise role of intestinal antibodies (production and deposition) in predicting villous atrophy.

The TG2 deposits technique has also been used in non-CD conditions, such as other gluten-related disorders and autoimmune conditions. A very high percentage of patients with DH and the totality of a small group with GA showed deposition of TG2 antibodies at the intestinal level. Data from T1D patients are puzzling, considering that 78 and 58% of T1D patients (serologically TG2 positive and negative, respectively) expressed TG2 deposits at the intestinal level. In T1D patients, a transient positivity of serological CD marker is frequently described at diagnosis ([@B34]). It is interesting to note that only TG2 deposits in T1D patients with positive serum TTG had the same molecular features of CD deposits. Therefore, it is not clear whether the presence of deposits is a further confirmation of a possible role of gluten in T1D development or is an unspecific autoimmune phenomenon in this group of patients.

It is a limitation of this review that a large proportion of the available data on intestinal deposits come from studies performed by two single European groups, in a relatively short period of time. Confirmation of these results is awaited from other groups and in different settings.

Conclusion {#S5}
==========

TG2 deposits are an appealing diagnostic tool, particularly in the setting of challenging CD diagnosis and refractory CD. The value as a prognostic marker in early stage CD has not clearly been established. Overall, the costs and benefits of performing this test need to be very well balanced, considering the technical difficulties and the high costs of the exam.

Conflict of Interest Statement {#S6}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: Yeong Yeh Lee, University of Glasgow, UK

[^2]: Reviewed by: Govind K. Makharia, All India Institute of Medical Sciences, India; Ruggiero Francavilla, University of Bari, Italy

[^3]: This article was submitted to Gastroenterology, a section of the journal Frontiers in Medicine.
